A detailed history of Roman Butler Fullerton & CO transactions in Eli Lilly & CO stock. As of the latest transaction made, Roman Butler Fullerton & CO holds 10,027 shares of LLY stock, worth $7.96 Million. This represents 2.66% of its overall portfolio holdings.

Number of Shares
10,027
Previous 9,905 1.23%
Holding current value
$7.96 Million
Previous $8.97 Million 0.94%
% of portfolio
2.66%
Previous 3.04%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

BUY
$772.14 - $960.02 $94,201 - $117,122
122 Added 1.23%
10,027 $8.88 Million
Q2 2024

Jul 15, 2024

BUY
$724.87 - $909.04 $46,391 - $58,178
64 Added 0.65%
9,905 $8.97 Million
Q1 2024

Apr 29, 2024

BUY
$592.2 - $792.28 $31,386 - $41,990
53 Added 0.54%
9,841 $7.66 Million
Q4 2023

Jan 31, 2024

SELL
$525.19 - $619.13 $93,483 - $110,205
-178 Reduced 1.79%
9,788 $5.71 Million
Q3 2023

Oct 18, 2023

BUY
$434.7 - $599.3 $36,514 - $50,341
84 Added 0.85%
9,966 $5.35 Million
Q2 2023

Jul 25, 2023

BUY
$350.74 - $468.98 $194,309 - $259,814
554 Added 5.94%
9,882 $4.63 Million
Q1 2023

Apr 27, 2023

SELL
$310.63 - $364.82 $456,315 - $535,920
-1,469 Reduced 13.61%
9,328 $3.2 Million
Q4 2022

Jan 23, 2023

SELL
$321.55 - $374.67 $3,537 - $4,121
-11 Reduced 0.1%
10,797 $0
Q3 2022

Oct 17, 2022

SELL
$296.48 - $337.87 $549,377 - $626,073
-1,853 Reduced 14.64%
10,808 $3.54 Million
Q2 2022

Jul 26, 2022

BUY
$278.73 - $327.27 $1.35 Million - $1.58 Million
4,833 Added 61.74%
12,661 $4.2 Million
Q1 2022

May 05, 2022

BUY
$234.69 - $291.66 $1.06 Million - $1.31 Million
4,507 Added 135.71%
7,828 $2.24 Million
Q4 2021

Jan 24, 2022

BUY
$224.85 - $279.04 $224 - $279
1 Added 0.03%
3,321 $917,000
Q3 2021

Nov 10, 2021

SELL
$221.6 - $272.71 $5,096 - $6,272
-23 Reduced 0.69%
3,320 $793,000
Q2 2021

Jul 29, 2021

BUY
$180.55 - $233.54 $361 - $467
2 Added 0.06%
3,343 $767,000
Q1 2021

Apr 22, 2021

BUY
$164.32 - $212.72 $72,793 - $94,234
443 Added 15.29%
3,341 $621,000
Q4 2020

Feb 01, 2021

BUY
$130.46 - $172.63 $29,483 - $39,014
226 Added 8.46%
2,898 $489,000
Q3 2020

Oct 15, 2020

BUY
$146.22 - $169.13 $292 - $338
2 Added 0.07%
2,672 $395,000
Q2 2020

Jul 28, 2020

BUY
$136.42 - $164.18 $136 - $164
1 Added 0.04%
2,670 $438,000
Q1 2020

Apr 13, 2020

BUY
$119.05 - $147.35 $238 - $294
2 Added 0.07%
2,669 $370,000
Q4 2019

Jan 27, 2020

BUY
$106.92 - $132.43 $106 - $132
1 Added 0.04%
2,667 $351,000
Q3 2019

Oct 15, 2019

SELL
$106.79 - $116.16 $35,133 - $38,216
-329 Reduced 10.98%
2,666 $298,000
Q2 2019

Jul 22, 2019

BUY
$110.79 - $129.32 $443 - $517
4 Added 0.13%
2,995 $332,000
Q1 2019

Apr 24, 2019

BUY
$111.31 - $131.02 $114,649 - $134,950
1,030 Added 52.52%
2,991 $388,000
Q4 2018

Feb 04, 2019

BUY
$105.9 - $118.64 $207,669 - $232,653
1,961 New
1,961 $227,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $755B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Roman Butler Fullerton & CO Portfolio

Follow Roman Butler Fullerton & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Roman Butler Fullerton & CO, based on Form 13F filings with the SEC.

News

Stay updated on Roman Butler Fullerton & CO with notifications on news.